In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 10242-11-2, name is 5-Bromobenzofuran-2-carboxylic acid, introducing its new discovery. Formula: C9H5BrO3
5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2, 3-dimethoxybenzamide 1 is a potent and selective sigma2 receptor ligand suitable for further development. A series of new analogues, incorporating a variety of isoquinoline and carboxylic acid moieties, linked together with either a linear or cyclic amine spacer have been synthesised and assessed for their sigma1/sigma2 binding affinity and selectivity. Compounds with a rigid piperidine spacer gave Ki values for the sigma2 receptor between 8.7-845 nM. Changing the configuration of the methoxy groups on the isoquinoline moiety resulted in molecules with sigma2Ki values of 4.4-133 nM whereas varying the length and flexibility of the carbon spaces gave sigma2Ki values 0.88-15.0 nM, some of the most active, selective sigma2 ligands to date. Thus, the flexibility and length of the carbon linker and the carboxylic acid moiety are confirmed to be key to the exceptional binding affinity and selectivity for this active series. Additionally, the incorporation of a halogen on selected carboxylic acid moieties provided a convenient strategy for the introduction of a radiohalogen for applications in pharmacological and imaging studies.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 10242-11-2, and how the biochemistry of the body works.Formula: C9H5BrO3
Reference：
Benzofuran – Wikipedia,
Benzofuran | C8H3916O – PubChem